MedPage Today on MSN

Novel Mimetic Bispecific Antibody Superior to Standard Care in Hemophilia A

Mim8 prophylaxis significantly reduced bleeding events in patients with or without inhibit ...
Le Lézard

Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM

Today, the New England Journal of Medicine (NEJM) published 26-week results from the phase 3 FRONTIER2 trial evaluating the efficacy and safety of once-monthly and once-weekly denecimig (Mim8) in ...